Is there a threat of stricter regulation of CBD within the EU?

As promised, we have become more familiar with the situation and here are the clarifications and reactions to the reports in our media.

Our reaction:

The title of the article “Cannabis preparations in danger. Brussels wants to classify them as drugs” is misleading. In the quoted statement, the European Commission only states that, although CBD extracted from hemp (if not synthesized) is not explicitly listed in the lists of the international conventions on narcotic drugs of 1961, it is included in the list of the Single Convention on Narcotic Drugs under the item “hemp and hemp resin and extracts and tinctures of hemp”. This means that it falls under international control. The intention of the European Commission, as we understand it, is not to ban or restrict the sale of medicinal cannabis preparations containing CBD. This sale is permitted by the Single Convention on Narcotic Drugs of 1961 and is fully in the hands of individual states. The exception is the WHO recommendation for CBD products, which are now under international control. However, it is intended that these products with a THC content of up to 0.2% be excluded from control.

In general: The European Commission treats CBD as a novel food (new foods that were not consumed to a significant extent in EU countries before May 15, 1997) in the following three ways:

CBD extracted from hemp flowers is prohibited, for CBD extracted from the rest of the plant, the EC will assess each application for its approval as a novel food, and for synthetic CBD, which will be recognized as a novel food, individual applications will not have to be assessed at all.